| scholarly article | Q13442814 |
| P50 | author | Thor D Stein | Q34445851 |
| Jacob M. Hooker | Q52280455 | ||
| P2093 | author name string | Benjamin Wolozin | |
| Haihao Zhu | |||
| Neil Kowall | |||
| Xiehua Xue | |||
| Wei Qiao Qiu | |||
| Qiushan Tao | |||
| Hana Na | |||
| Erming Wang | |||
| Max Wallack | |||
| P2860 | cites work | Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation | Q22008492 |
| Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry | Q24299193 | ||
| Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism | Q24307623 | ||
| p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5 | Q24320432 | ||
| RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor | Q24323946 | ||
| Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history | Q24338152 | ||
| Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets | Q26865654 | ||
| Amylin at the interface between metabolic and neurodegenerative disorders | Q27003342 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product | Q28138337 | ||
| CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation | Q28245143 | ||
| Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 | ||
| Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways | Q30175699 | ||
| Reduced IGF-1 signaling delays age-associated proteotoxicity in mice | Q30497845 | ||
| Islet amyloid polypeptide in the islets of Langerhans: friend or foe? | Q33976606 | ||
| On the Relation of Chronic Interstitial Pancreatitis to the Islands of Langerhans and to Diabetes Melutus | Q34019932 | ||
| Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. | Q34167833 | ||
| Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation | Q34336783 | ||
| Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. | Q34349457 | ||
| Amylin deposition in the brain: A second amyloid in Alzheimer disease? | Q34352928 | ||
| Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates | Q34672360 | ||
| Actions of β-amyloid protein on human neurons are expressed through the amylin receptor | Q34760866 | ||
| Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures | Q34779219 | ||
| Cdk5: One of the links between senile plaques and neurofibrillary tangles? | Q35116571 | ||
| GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities | Q36153247 | ||
| Central nervous system and other effects | Q36402880 | ||
| G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics | Q36742422 | ||
| Positive association between plasma amylin and cognition in a homebound elderly population | Q36807576 | ||
| Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. | Q37297656 | ||
| Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease | Q37331433 | ||
| Modulating receptor function through RAMPs: can they represent drug targets in themselves? | Q37371266 | ||
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. | Q37391481 | ||
| The role of G protein-coupled receptors in the pathology of Alzheimer's disease | Q37830311 | ||
| Solanezumab for the treatment of mild-to-moderate Alzheimer's disease | Q37979840 | ||
| The interaction of amylin with other hormones in the control of eating | Q38031993 | ||
| Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology | Q38062765 | ||
| Janus faces of amyloid proteins in neuroinflammation | Q38202911 | ||
| Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease? | Q38239648 | ||
| Differential expression of membrane sialoglycoproteins in exudate and resident mouse peritoneal macrophages | Q38343959 | ||
| Amylin: Pharmacology, Physiology, and Clinical Potential | Q38526856 | ||
| Amylin-mediated control of glycemia, energy balance, and cognition | Q38753342 | ||
| Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model. | Q39136356 | ||
| Multiple target of hAmylin on rat primary hippocampal neurons | Q39288319 | ||
| Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity | Q40975717 | ||
| A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage | Q41183035 | ||
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease | Q42710153 | ||
| Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats | Q42852579 | ||
| G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse | Q43070751 | ||
| An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures | Q44564031 | ||
| Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization | Q44833066 | ||
| Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study | Q46373170 | ||
| Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin | Q47849481 | ||
| Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus | Q47983953 | ||
| Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. | Q48114139 | ||
| Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor | Q48273018 | ||
| Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. | Q48404445 | ||
| Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease | Q48445250 | ||
| Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. | Q48869814 | ||
| Quantitative neurohistological features of frontotemporal degeneration | Q49140415 | ||
| Microglial alterations in human Alzheimer's disease following Aβ42 immunization. | Q53282250 | ||
| Effects of sequential proline substitutions on amyloid formation by human amylin20-29. | Q54128400 | ||
| Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 | Q60603655 | ||
| Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. | Q64965686 | ||
| Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors | Q71013459 | ||
| Permeability of the blood-brain barrier to amylin | Q71520909 | ||
| Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes | Q71809920 | ||
| Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity | Q72621646 | ||
| Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain | Q73843429 | ||
| The immunophenotype of perivascular cells in the human brain | Q73878411 | ||
| Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study | Q84343828 | ||
| Emerging therapeutics for Alzheimer's disease | Q87039918 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 170-181 | |
| P577 | publication date | 2017-03-28 | |
| P1433 | published in | Neuropharmacology | Q15332439 |
| P1476 | title | Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease | |
| P478 | volume | 119 |
| Q48099438 | Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents |
| Q90070082 | Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology? |
| Q39320824 | Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease |
| Q89947927 | Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts |
| Q47322028 | Amylin in Alzheimer's disease: Pathological peptide or potential treatment? |
| Q92747901 | Association of Plasma Amylin Concentration With Alzheimer Disease and Brain Structure in Older Adults |
| Q89955963 | Characterization of the effects of calcitonin gene-related peptide receptor antagonist for Alzheimer's disease |
| Q91883726 | Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons |
| Q92804142 | Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease |
| Q57069272 | Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition |
| Q51246561 | Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease. |
| Q42376572 | Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation |
| Q50181740 | Structural Modulation of Human Amylin Protofilaments by Naturally-Occurring Mutations |
| Q59792740 | Sub-Toxic Human Amylin Fragment Concentrations Promote the Survival and Proliferation of SH-SY5Y Cells via the Release of VEGF and HspB5 from Endothelial RBE4 Cells |
Search more.